The evidence for switching dibenzazepines in people with epilepsy
dc.contributor.author | Watkins, L | |
dc.contributor.author | O'Dwyer, M | |
dc.contributor.author | Oak, K | |
dc.contributor.author | Lawthom, C | |
dc.contributor.author | Maguire, M | |
dc.contributor.author | Thomas, R | |
dc.contributor.author | Shankar, R | |
dc.date.accessioned | 2020-04-09T08:48:00Z | |
dc.date.issued | 2020-04-06 | |
dc.description.abstract | The dibenzazepines particularly carbamazepine are associated with known adverse effects (AEs) and drug to drug interactions. Eslicarbazepine acetate (ESL) is structurally distinct from other members of the dibenzazepine family and has the advantage of once daily dosing. Observational and trial data report successful switching from older dibenzazepines to ESL. The evidence base for doing so is unclear and not standardised. This is a literature review following the PRISMA scoping guidelines identifying the evidence of switching dibenzazepines. Transition methods, ratios, tolerance to change, adverse effects and retention post change were evaluated. Study quality was assessed using the Oxford Centre for Evidence Based Medicine levels of evidence. Seven studies investigated the outcome of transition between carbamazepine and or oxcarbazepine to ESL, with specific data on the transition dose ratio and scheduling. The available data suggest that the overnight transition between oxcarbazepine and ESL in a 1:1 ratio (most common) is generally well tolerated with high retention rates. The transition showed improvement in adverse events associated with oxcarbazepine across a variety of domains. Almost 60% transitioned because of adverse events experienced no further symptoms at 12 months. There is less data on the transition from carbamazepine to ESL. The evidence available suggests an overnight transition in the ratio of 1:1.3-1.5. The retention rate following transition from carbamazepine to ESL was 69% (follow up of four months) with almost half of those transitioned because of adverse events experiencing no further symptoms. There is Grade C evidence available to help guide clinicians in the transition. | en_GB |
dc.identifier.citation | Published online 6 April 2020 | en_GB |
dc.identifier.doi | 10.1111/ane.13248 | |
dc.identifier.uri | http://hdl.handle.net/10871/120628 | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/32249420 | en_GB |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_GB |
dc.subject | Epilepsy | en_GB |
dc.subject | Eslicarbazepine acetate | en_GB |
dc.subject | efficacy | en_GB |
dc.subject | safety | en_GB |
dc.subject | switch | en_GB |
dc.subject | tolerability | en_GB |
dc.title | The evidence for switching dibenzazepines in people with epilepsy | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-04-09T08:48:00Z | |
exeter.place-of-publication | Denmark | en_GB |
dc.description | This is the author accepted manuscript. The final version is available on open access from Wiley via the DOI in this record | en_GB |
dc.identifier.eissn | 1600-0404 | |
dc.identifier.journal | Acta Neurologica Scandinavica | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2020-04-06 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-04-09T08:46:41Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2020-04-09T08:48:08Z | |
refterms.panel | A | en_GB |
refterms.depositException | publishedGoldOA |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.